Concepedia

Van K. Morris

VK

Statistics

Publications

96

Citations

7.6K

H-Index

39

Active since

2010

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Guardant (United States)

Vanderbilt University

Vanderbilt-Ingram Cancer Center

Memorial Sloan Kettering Cancer Center

Van K. Morris is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and colorectal cancer.

ORCID

Publications per year

2010–2025

96

Publications

96

Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer

Scott Kopetz, Axel Grothey, Rona Yaeger et al. · New England Journal of Medicine · 2019 · 1.5K citations · Full text

, , +17

Phase II Pilot Study of Vemurafenib in Patients With Metastatic <i>BRAF</i> -Mutated Colorectal Cancer

Scott Kopetz, Jayesh Desai, Emily Chan et al. · Journal of Clinical Oncology · 2015 · 693 citations · Full text

, , +17

Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study

Van K. Morris, Mohamed E. Salem, Halla Nimeiri et al. · The Lancet Oncology · 2017 · 393 citations

, , +12

Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)

Scott Kopetz, Katherine A. Guthrie, Van K. Morris et al. · Journal of Clinical Oncology · 2020 · 391 citations · Full text

, , +13

Clinical and molecular characterization of early‐onset colorectal cancer

Alexandra N. Willauer, Yusha Liu, Allan Andresson Lima Pereira et al. · Cancer · 2019 · 365 citations · Full text

, , +17

1–5 of 96